Next-gen obesity treatment from Novo Nordisk misses mark in pivotal trial

Novo Nordisk’s next-generation obesity candidate led patients to lose a substantial amount of weight in a pivotal study but fell short of expectations, results that cast into doubt the future competitiveness of the company in the booming weight loss market.

The treatment, called CagriSema, led patients to lose 20% of their weight at 68 weeks in a late-stage study when looking at all participants, including those who dropped out, Novo said Friday. It led to 23% weight loss when considering only the participants who stuck with treatment. The company had earlier projected weight loss of about 25%.

Shares of Novo sank 20% in early Friday trading.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Study reveals anti-inflammatory power of Black Soldier Fly Larvae oil in inflammatory-related conditions

New study reveals the anti-inflammatory power of Black Soldier Fly Larvae (BSFL) oil, shedding light on its potential to alleviate inflammation in conditions like ulcerative

August 22, 2023

£85 million funding to support the international community in tackling antimicrobial resistance

Funding of £85 million will be announced at a global event to support the international community in tackling the growing threat of antimicrobial resistance.

May 16, 2024

Excessive drinking during the pandemic increased alcoholic liver disease death rates

Excessive drinking during the covid-19 pandemic increased alcoholic liver disease deaths so much that the condition killed more Californians than car accidents or breast cancer,

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.